Arbutus to report second quarter 2021 financial results and provide corporate update

Warminster, pa., july 29, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis b virus (hbv) infection, as well as therapies to treat coronaviruses (including covid-19), today announced that it has scheduled its second quarter 2021 financial results and corporate update for thursday, august 5, 2021. the schedule for the press release and conference call/webcast are as follows:
ABUS Ratings Summary
ABUS Quant Ranking